2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Based on previous retrospective results, we investigated the association of coagulation FXIII subunit A (FXIII-A) expression pattern on survival and correlations with known prognostic factors of B-cell progenitor (BCP) childhood acute lymphoblastic leukemia (ALL) as a pilot study of the prospective multi-center BFM ALL-IC 2009 clinical trial. Methods: The study included four national centers ( n = 408). Immunophenotyping by flow cytometry and cytogenetic analysis were performed by standard methods. Copy number alteration was studied in a subset of patients ( n = 59). Survival rates were estimated by Kaplan-Meier analysis. Correlations between FXIII-A expression patterns and risk factors were investigated with Cox and logistic regression models. Results: Three different patterns of FXIII-A expression were observed: negative (<20%), dim (20–79%), and bright (≥80%). The FXIII-A dim expression group had significantly higher 5-year event-free survival (EFS) (93%) than the FXIII-A negative (70%) and FXIII-A bright (61%) groups. Distribution of intermediate genetic risk categories and the “B-other” genetic subgroup differed significantly between the FXIII-A positive and negative groups. Multivariate logistic regression confirmed independent association between the FXIII-A negative expression characteristics and the prevalence of intermediate genetic risk group. Conclusions: FXIII-A negativity is associated with dismal survival in children with BCP-ALL and is an indicator for the presence of unfavorable genetic alterations.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Acute lymphoblastic leukaemia.

          Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine. Copyright © 2013 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Genetic Basis of Acute Lymphoblastic Leukemia

            Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an important cause of morbidity and mortality in children and adults. The past decade has been marked by extraordinary advances into the genetic basis of leukemogenesis and treatment responsiveness in ALL. Both B-cell and T-cell ALL comprise multiple subtypes harboring distinct constellations of somatic structural DNA rearrangements and sequence mutations that commonly perturb lymphoid development, cytokine receptors, kinase and Ras signaling, tumor suppression, and chromatin modification. Recent studies have helped to understand the genetic basis of clonal evolution and relapse and the role of inherited genetic variants in leukemogenesis. Many of these findings are of clinical importance, and ongoing studies implementing clinical sequencing in the management of leukemia are expected to improve diagnosis, monitoring of residual disease, and early detection of relapse and to guide precise therapies. Here, we provide a concise review of genomic studies in ALL and discuss the role of genomic testing in clinical management.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).

              Criteria for the immunological classification of acute leukemias are proposed by a recently established European group designated EGIL. The main aims of EGIL are to establish guidelines for the characterization of acute leukemias based on marker expression and provide a uniform basis for the diagnosis of the various types of these hemopoietic malignancies which should be helpful for future multinational clinical and laboratory investigations. Within the two major types (B and T cell lineage) of acute lymphoblastic leukemia (ALL), several groups are delineated according to the degree of cell differentiation. Within the acute myeloid leukemias (AML), only three subtypes as defined by the FAB classification: M0-AML, M6-AML and M7-AML, can be unequivocally defined by immunological markers; prospective studies are undertaken to see whether characteristic immunological profiles are associated with particular AML subtypes defined by specific cytogenetic abnormalities. Criteria for the definition of biphenotypic acute leukemia (BAL) are devised and a scoring system is outlined aimed to distinguish BAL from those acute leukemias with expression of a marker from another lineage. In addition, an uncommon subset of acute leukemias with no evidence of lymphoid or myeloid differentiation is recognized and the useful panel of markers to investigate and establish the cell nature of the acute leukemias is outlined. EGIL will focus in the future on testing the reproducibility of the proposed guidelines, particularly those for BAL, assessing their clinical value within a framework of multicentric trials and setting up uniform methodological criteria.
                Bookmark

                Author and article information

                Journal
                Cancers (Basel)
                Cancers (Basel)
                cancers
                Cancers
                MDPI
                2072-6694
                13 August 2020
                August 2020
                : 12
                : 8
                : 2264
                Affiliations
                [1 ]Department of Laboratory of Medicine, University of Debrecen, 4032 Debrecen, Hungary; karai.bettina@ 123456med.unideb.hu (B.K.); ujfalusi.aniko@ 123456med.unideb.hu (A.U.); szantho.eszter@ 123456med.unideb.hu (E.S.); kappelmayer@ 123456med.unideb.hu (J.K.)
                [2 ]Department of Pediatrics, University of Debrecen, 4032 Debrecen, Hungary; katalingyurina@ 123456gmail.com (K.G.); iszegedi@ 123456med.unideb.hu (I.S.)
                [3 ]Department of Microbiology and Immunology, Medical University of Silesia, 40-055 Katowice, Poland; lsedek@ 123456sum.edu.pl
                [4 ]1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary; barna.gabor@ 123456med.semmelweis-univ.hu
                [5 ]Department of Pathology, Scientific University of Pécs, 7622 Pécs, Hungary; jakso.pal@ 123456pte.hu
                [6 ]Department of Pediatric Hematology and Oncology, National Institute of Children’s Diseases and Comenius University Bratislava, 833 40 Bratislava, Slovakia; peter.svec@ 123456gmail.com (P.S.); sasa.kolenova@ 123456gmail.com (A.K.)
                [7 ]Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, 4028 Debrecen, Hungary; nagy.attila@ 123456sph.unideb.hu
                [8 ]2nd Department of Pediatrics, Semmelweis University, 1094 Budapest, Hungary; muller.judit@ 123456med.semmelweis-univ.hu (J.M.); kovacs.gabor1@ 123456med.semmelweis-univ.hu (G.T.K.)
                [9 ]Department of Pediatric Hematology-Oncology, BAZ county university hospital pediatric center, 3526 Miskolc, Hungary; reka.simondr@ 123456gmail.com
                [10 ]Department of Pediatrics, Scientific University of Pécs, 7622 Pécs, Hungary; vojczeka@ 123456gmail.com
                [11 ]Department of Pediatrics, Scientific University of Szeged, 6720 Szeged, Hungary; tiszlaviczlilla@ 123456yahoo.com
                [12 ]Department of Pediatric Hematology, Oncology and Transplantology, Lublin Medical University, 20-059 Lublin, Poland; jerzy.kowalczyk@ 123456uszd.lublin.pl
                [13 ]Department of Pediatric Hematology and Oncology, Medical University of Silesia Zabrze, 41-808 Zabrze, Poland; szczep57@ 123456poczta.onet.pl
                [14 ]Children’s Cancer Research Institute and St. Anna Children’s Hospital, Pediatric Clinic, Medical University of Vienna, 1090 Vienna, Austria; michael.dworzak@ 123456stanna.at (M.D.); angela.schumich@ 123456ccri.at (A.S.); andishe.attarbaschi@ 123456stanna.at (A.A.); karin.nebral@ 123456labdia.at (K.N.); oskar.haas@ 123456labdia.at (O.A.H.)
                Author notes
                [* ]Correspondence: hevessy@ 123456med.unideb.hu (Z.H.); kisscs@ 123456med.unideb.hu (C.K.); Tel.: +36-30-591-1998 (C.K.)
                Author information
                https://orcid.org/0000-0002-5986-3236
                https://orcid.org/0000-0002-7647-2253
                https://orcid.org/0000-0003-3080-0845
                https://orcid.org/0000-0001-9924-1645
                https://orcid.org/0000-0001-5336-261X
                https://orcid.org/0000-0003-4300-5533
                https://orcid.org/0000-0002-9285-6898
                https://orcid.org/0000-0001-7334-454X
                https://orcid.org/0000-0002-7364-9906
                https://orcid.org/0000-0001-5170-5965
                Article
                cancers-12-02264
                10.3390/cancers12082264
                7463512
                32823516
                8ce314b7-3f87-426f-9963-ea025243b570
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 20 June 2020
                : 10 August 2020
                Categories
                Article

                children,acute lymphoblastic leukemia,b-cell progenitor,factor xiii subunit a,genetic risk categories,survival,middle-income countries

                Comments

                Comment on this article